

Fabrice Barlesi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/379562/fabrice-barlesi-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

17,674
citations

33
h-index

114
g-index

114
ext. papers

23,370
ext. citations

9.6
avg, IF

6.17
L-index

#	Paper	IF	Citations
100	Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.. <i>Lung Cancer</i> , 2022 , 167, 41-48	5.9	0
99	Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. <i>Lung Cancer</i> , 2022 , 169, 31-39	5.9	
98	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.. <i>Lancet Oncology, The</i> , 2021 ,	21.7	7
97	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1253-1263 ^{2.2}		22
96	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. <i>Lung Cancer</i> , 2021 , 154, 92-98	5.9	2
95	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021 , 11, 874-899	24.4	26
94	Imaging: towards a global solution to overcome the cancer pandemic. <i>Lancet Oncology, The</i> , 2021 , 22, 430-432	21.7	
93	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 807-816	8.9	4
92	Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301-SAFIR02-LUNG intergroup trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9095-9095	2.2	
91	ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , 2021 , 17, 1709-1719	3.6	4
90	Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 947-956	4	2
89	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021 , 28, 3297-3315	12.7	7
88	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 653-664	8.9	68
87	Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?. <i>Lung Cancer</i> , 2021 , 152, 86-93	5.9	2
86	Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients. <i>Nature Communications</i> , 2021 , 12, 634	17.4	51
85	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors 2021 , 9,		4
84	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021 , 153, 123-132	7.5	8

83	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1369-1378	8.9	5
82	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021 , 39, 1039-1041	24.3	0
81	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	11
80	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1647-1662	8.9	48
79	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data.. <i>Cancers</i> , 2021 , 13,	6.6	2
78	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100068	1.4	3
77	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology, The</i> , 2020 , 21, 914-922	21.7	328
76	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 914-947	8.9	71
75	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancéologie Thoracique Biomarkers France Study by Mutation Subtypes. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100052	1.4	3
74	Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 860-866	8.9	33
73	Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. <i>Lancet Oncology, The</i> , 2020 , 21, 607-608	21.7	6
72	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. <i>European Journal of Cancer</i> , 2020 , 131, 27-36	7.5	15
71	Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study. <i>Oncotarget</i> , 2020 , 11, 4648-4654	3.3	6
70	Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: A contemporary clinical practice patterns study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9592-9592	2.2	3
69	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , 2020 , 21, 261-270	21.7	154
68	Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial. <i>European Journal of Cancer</i> , 2020 , 138, 193-201	7.5	1
67	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020 , 10, 578756	5.3	17
66	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020 , 182, 1401-1418.e18	56.2	359

65	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020 , 22, 107	6.3	2
64	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. <i>Nature Cancer</i> , 2020 , 1, 965-975	15.4	58
63	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
62	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. <i>Pharmaceutics</i> , 2020 , 12,	6.4	4
61	Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. <i>Clinical Lung Cancer</i> , 2020 , 21, e10-e14	4.9	10
60	High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 120-124	8.9	13
59	Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France). <i>Clinical Lung Cancer</i> , 2020 , 21, 56-65.e8	4.9	13
58	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , 2020 , 26, 665-671	50.5	201
57	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2020-2031	59.2	960
56	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. <i>Lung Cancer</i> , 2019 , 134, 245-253	5.9	23
55	Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. <i>European Journal of Cancer</i> , 2019 , 116, 86-97	7.5	14
54	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 793-801	8.9	28
53	Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 429-438	3.8	2
52	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1095-1101	8.9	85
51	Functional status in a geriatric oncology setting: A review. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 884-894	3.6	18
50	Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. <i>Therapeutic Advances in Respiratory Disease</i> , 2019 , 13, 1753466619831906	4.9	18
49	An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. <i>PLoS ONE</i> , 2019 , 14, e0220988	3.7	12
48	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3011-3011	2.2	9

47	IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9012-9012	2.2	5
46	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase ()-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. <i>Lung Cancer: Targets and Therapy</i> , 2019 , 10, 125-130	2.9	5
45	Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 11-17	3.5	5
44	Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, 201-207	4.9	81
43	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2018 , 19, 301-314	4.9	6
42	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 576-584	8.9	45
41	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. <i>European Respiratory Review</i> , 2018 , 27,	9.8	14
40	Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer. <i>Quality of Life Research</i> , 2018 , 27, 555-565	3.7	1
39	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1248-1268	8.9	331
38	Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation?. <i>Cells</i> , 2018 , 7,	7.9	9
37	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer). <i>ESMO Open</i> , 2018 , 3, e000394	6	1
36	Adjuvant treatment patterns and outcomes in patients with stage IB-IIIa non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. <i>Lung Cancer</i> , 2018 , 124, 310-316	5.9	11
35	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018 , 378, 2288-2301	59.2	1695
34	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. <i>British Journal of Cancer</i> , 2018 , 118, 38-42	8.7	14
33	The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018 , 7, 639-646	4.4	61
32	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , 2018 , 19, 1468-1479	21.7	237
31	ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?. <i>ESMO Open</i> , 2018 , 3, e000419	6	17
30	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1156-1170	8.9	134

29	Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. <i>Clinical Lung Cancer</i> , 2018 , 19, e823-e830	4.9	8
28	Economic burden of resected (stage IB-IIIa) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). <i>Lung Cancer</i> , 2018 , 124, 298-309	5.9	12
27	Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e81-e84	8.9	33
26	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1844-1853	27.4	211
25	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. <i>British Journal of Cancer</i> , 2017 , 116, 1505-1512	8.7	19
24	Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. <i>International Journal of Cardiology</i> , 2017 , 241, 387-392	3.2	21
23	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 255-265	4.0	2681
22	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). <i>Journal of Clinical Oncology</i> , 2017 , 35, 3924-3933	2.2	495
21	Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?. <i>World Neurosurgery</i> , 2017 , 107, 1047.e1-1047.e4	2.1	6
20	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017 , 26,	9.8	28
19	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017 , 136, 2085-2087	16.7	230
18	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. <i>European Journal of Cancer</i> , 2017 , 82, 27-33	7.5	20
17	Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 99	3	8
16	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. <i>International Journal of Cardiology</i> , 2016 , 224, 366-375	3.2	19
15	A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. <i>BMC Cancer</i> , 2016 , 16, 278	4.8	18
14	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 984-993	21.7	498
13	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. <i>Cancer Research</i> , 2016 , 76, 4931-40	10.1	84
12	Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 198-208	5.4	34

11	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016 , 387, 1415-1426	40	581
10	Elderly selection on geriatric index assessment. <i>Annals of Translational Medicine</i> , 2016 , 4, 245	3.2	1
9	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 642-50	21.7	269
8	Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). <i>Lung Cancer</i> , 2015 , 89, 139-45	5.9	8
7	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2667-74	2.2	200
6	Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. <i>Journal of Clinical Oncology</i> , 2015 , 33, 992-9	2.2	266
5	Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter. <i>Clinical Cancer Research</i> , 2015 , 21, 934	12.9	
4	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 1627-39	59.2	5964
3	Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. <i>European Respiratory Journal</i> , 2015 , 46, 1440-50	13.6	5
2	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. <i>Seminars in Cancer Biology</i> , 2015 , 35, 53-61	12.7	50
1	A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015 , 20, 783-90	1.8	5